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Abstract
Purpose of review Autonomic dysfunction is common in dementia, particularly in the Lewy
body dementias. This review considers the evidence for autonomic dysfunction in demen-
tia, common symptoms and potential management options.
Recent findings Autonomic dysfunction has been shown in Alzheimer’s disease and
Lewy body dementias. Common symptoms include orthostatic dizziness, syncope,
falls, urinary tract symptoms and constipation. Non-pharmacological management of
orthostatic hypotension should include bolus water drinking. Pharmacological man-
agement may include the use of midodrine or droxidopa although the latter is not
available in Europe. Atomoxetine is a noradrenaline reuptake inhibitor which may be
useful if further clinical trials become available. Management of constipation may
include the use o f probiotics, osmotic laxatives such as macrogol and chloride type
2 channel activators such as lubiprostone. Management of urinary tract symptoms
may include the use of mirabegron.
Summary There is a dearth of clinical trials for autonomic dysfunction in dementia
and most of the evidence is imputed from trials in Parkinson’s disease. However,
pragmatic recommendations may be made. There is a need for controlled clinical
trials in people with dementia.
Introduction
The autonomic or “involuntary” nervous system (ANS)
is responsible for the control of many bodily functions
that we are not usually aware of, such as heart rate,
blood pressure, body temperature, saliva and tear pro-
duction, pupil size, gut motility and sphincter control. It
is one of the most fundamental homeostatic mecha-
nisms within mammalian physiology and can be dis-
turbed in many disease processes. There is a reason to
believe that the ANS may be affected by dementia as
neuropathological lesions can be found in the ANS in
many types of dementia. In Alzheimer’s disease (AD),
lesions have been found in the insula and anterior cin-
gulate cortex [1]. ANS dysfunction is a common feature
of the Lewy body disorders which include Parkinson’s
disease dementia (PDD) and dementia with Lewy bod-
ies (DLB) [2•]. Aggregates of misfolded alpha-
synuclein are deposited in the neurons, including
axons, forming Lewy bodies and Lewy neurites. These
are found in the post-synaptic peripheral autonomic
neurons. DLB is also associated with underactivity of
the cholinergic nervous system [3]. Acetylcholine is
essential for parasympathetic and pre-ganglionic sym-
pathetic neurotransmission.
Common symptoms of ANS dysfunction are
outlined in Table 1 and include orthostatic dizziness,
syncope, falls, urinary tract symptoms and constipation.
Orthostatic symptoms are typically worse in the morn-
ing, after meals, during a rise in body temperature, with
prolonged standing, and with physical activity. Total
autonomic symptom scores, urinary symptoms, consti-
pation and postural dizziness have been shown to be
significantly higher in PDD, DLB and vascular dementia
(VAD) patients than either controls or AD patients and
are associated with reduced activities of daily living,
depression and poorer quality of life [4]. Falls are a
particularly significant symptom as they are associated
with the subsequent decline in activities of daily living,
institutionalisation and mortality. Orthostatic hypoten-
sion has been shown to be a risk factor for falls in
dementia [5]. Orthostatic hypotension may be associat-
ed with poorer cognitive prognosis in Parkinson’s dis-
ease (PD), but whether this is due to causation or asso-
ciation with more severe underlying disease is unclear
[6, 7].
A number of studies have examined ANS dysfunc-
tion in dementia. The results in AD have been conflict-
ing, with some studies showing evidence of ANS dys-
function [8–12] and some studies showing that some
patients may have evidence of autonomic neuropathy
but as a group, no deficits in heart rate variability [13•,
14]. A recent meta-analysis of heart rate variability stud-
ies in AD also showed conflicting evidence with deficits
in the time domain rather than the frequency domain
and high heterogeneity of results [15]. VADmay also be
associated with some ANS dysfunction, but again the
evidence is conflicting [13•, 14, 16, 17]. However, as
Table 1. Symptoms of autonomic dysfunction
Symptoms of orthostatic hypotension Other autonomic symptoms
Light-headedness or dizziness
Syncope
Falls
Weakness
Fatigue
Head and neck pain (coat hanger pain)
Vertigo
Pallor
Clamminess
Blurred vision
Palpitations
Tremulousness
Cognitive difficulties
Anxiety
Bloating, nausea and vomiting
Dysphagia
Dry mouth or sialorrhoea
Dry eyes
Loss of sweating or excessive sweating
Sensitivity to glare
Diarrhoea and constipation
Urinary frequency, urgency and urge incontinence
Urinary retention
Erectile dysfunction
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expected, the most prominent ANS dysfunction has
been shown in the Lewy body dementias [13•, 18–21].
The study of orthostatic hypotension (OH) alone may
indicate some ANS dysfunctions, and OH has been
shown to be more common in all types of dementia,
but other factors may also contribute toOH in dementia
[13•, 22–24]. Orthostatic hypotension may be asymp-
tomatic in dementia [25].
Diagnosis
Clinical autonomic function test ing usually focuses upon the
neurocardiovascular system as this can be investigated non-invasively. Com-
monly used tests include the measurement of orthostatic changes in blood
pressure and heart rate, the cardiovascular responses to the Valsalva manoeuvre
(expiration against a closed glottis), respiratory sinus arrhythmia during respi-
ration at a controlled frequency, response to a cold stimulus (cold pressor test)
and isometric exercise [26]. Abnormalities in more than 3 of these tests are
usually taken as an indication of clinically significant autonomic failure [27].
Alternatively, a composite scoring system may be used which has been shown
to correlate with severity of disease and prognosis in other common causes of
autonomic neuropathy [28]. In the clinic, a simple measurement of orthostatic
blood pressure change is the most commonly used test. Orthostatic hypoten-
sion is defined in recent consensus criteria as a sustained reduction of systolic
blood pressure of at least 20 mmHg or diastolic blood pressure of 10 mmHg
within 3 min of standing or head-up tilt to at least 60° on a tilt table. In patients
with supine hypertension, a reduction in systolic blood pressure of 30 mmHg
may be a more appropriate criterion for orthostatic hypotension because the
magnitude of the orthostatic blood pressure fall is dependent on the baseline
blood pressure [29]. An active stand is probably preferable to a tilt test as it
reproduces normal activity. It is not clear whether intermittent blood pressure
measurement or beat-to-beat measurement is most appropriate for the diagno-
sis of orthostatic hypotension. The beat-to-beat measurement may detect some
transient drops in blood pressure which are of unknown prognostic significance
[30]. Baroreflex failure may result in supine hypertension in some patients.
Heart rate variability has been used to detect ANS dysfunction, but this is a
research tool and is not useful for the clinical diagnosis of ANS dysfunction.
Meta-iodobenzylguanidine (MIBG) is a physiological analogue of norepineph-
rine, and cardiac 123I-MIBG scintigraphy has previously been used as a non-
invasive method of screening for localmyocardial sympathetic nerve damage in
various cardiac and neurological diseases. The fourth consensus report of the
diagnostic criteria for DLB recommends that MIBG scanning may be used as a
biomarker of DLB [31].
The assessment of dysphagia may be undertaken by oropharyngeal
videofluoroscopy and constipation by measurement of stool transit time. Uri-
nary symptoms may be investigated by urodynamic testing which may show
neurogenic detrusor overactivity. Other methods of evaluation of autonomic
function include quantitative sudomotor axon testing, thermoregulatory sweat
testing, sympathetic skin response, microneurography, pupillography,
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measurement of tear production, nocturnal penile tumescence studies and
sphincter electromyography, but these are usually undertaken in specialist
centres.
Current treatment
There are few clinical trials which have examined the management of ANS
dysfunction specifically in dementia. Therefore, current management has to
be pragmatic and is guided by the evidence for the management of ANS
dysfunction in related populations. There is some evidence for themanagement
of OH in older people in general and there is also a body of evidence for the
management of ANS dysfunction in Parkinson’s disease which is of particular
relevance to the Lewy body dementias.
Orthostatic hypotension
Non-pharmacological interventions
Initial management ofOH is non-pharmacological. Other causes ofOHbesides
ANS dysfunction, such as dehydration and medications, should be sought and
treated. Hypotensive drugs have been reported to be associated with syncope in
dementia [32]. These include diuretics, nitrates, α-blockers and angiotensin-
converting enzyme inhibitors. However, the effect of stopping antihyperten-
sives onOH is not necessarily clear. Studies have shown an association between
antihypertensives and OH but these have been observational [33]. There is
some evidence from a randomised controlled trial of withdrawal of antihyper-
tensives that prevalence of OH was reduced in those who did withdraw the
drugs, but intention to treat analyses were not significant [34]. Conversely, the
SPRINT trial found a lower prevalence of OH in intensively treated patients, but
this did not apply to older groups and people with a standing BP of less than
115 mmHg were excluded from the study [35].
Patients should be given conservative advice about avoiding sudden changes
in posture, maintaining their fluid and salt intake to ensure adequate hydration,
eating smaller and more frequent meals and avoiding heat stressors such as hot
tubs. However, patients should avoid physical inactivity which worsens ANS
function due to physical deconditioning. Some experts recommend measuring
urinary sodium excretion to determine whether salt intake is adequate and if
not to replace salt with either increased dietary intake or salt tablets. Patients
who have a 24-h urinary sodium excretion of below 170 mmol can be treated
with 1–2-g supplemental sodium three times a day [36]. Elevating the head of
the bed has been recommended to reduce nocturia and supine hypertension
[36], but a systematic review did not find any evidence that this is effective [37].
Specific non-pharmacological interventions include bolus water drinking, phys-
ical counter-manoeuvres (standing cross-legged), lower limb compression and
abdominal compression [38]. A recent qualitative study has shown that phys-
ical counter-manoeuvres were the most popular non-pharmacological therapy
in older people as they are convenient, require no equipment and can be done
as required. However, people with dementia may have difficulty learning these
manoeuvres. Bolus water drinking (480 ml of room-temperature tap water, to
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consume as much as possible within 5 min) is also well tolerated and accept-
able to patients, but some do have concerns about urinary frequency. Lower
limb and abdominal compression were the least acceptable. Stockings may be
difficult to get on and aesthetically unpleasing and abdominal binders may be
uncomfortable [39]. In terms of efficacy, bolus water drinking has been found
to be the most efficacious intervention, followed by abdominal compression
and physical counter-manoeuvres. Compression stockings were the least effica-
cious [40].
Pharmacological interventions
If non-pharmacological measures are insufficient, then pharmacological inter-
ventions may be required. Midodrine is a prodrug whose metabolite,
desglymidodrine, is an agonist of α1 adrenoceptors that increase vascular
resistance and blood pressure. It may be used in Europe and the USA. It is the
only licensed pharmacological treatment for OH in the UK. A systematic review
of 7 trials including 325 patients has shown that midodrine increases the
standing BP but does not improve postural drop. However, there is some
evidence that symptoms are improved. Evidence is of low quality and further
trials are required [41]. Treatment is started at 2.5 mg once or twice daily and
may be increased up to 10 mg three times daily. The first dose should be taken
1 h before rising and the last dose at least 4 h before bedtime to avoid supine
hypertension. Side effects of midodrine include hypertension, scalp tingling
and piloerection. Contraindications are liver disease, severe heart disease, acute
kidney injury, urinary retention, phaeochromocytoma and thyrotoxicosis.
Droxidopa is a more recent drug for neurogenic OH which has mainly
been used in Japan but has now received FDA approval in the USA. It is
not licensed in Europe. Droxidopa is a norepinephrine prodrug that is
converted into norepinephrine both in the central nervous system and in
peripheral tissues, including sympathetic peripheral nerve endings. A
meta-analysis of four trials including 494 patients showed that it was
effective in reducing dizziness, overall symptoms and difficulty with
activity. Droxidopa was also effective in improving standing systolic
blood pressure [42•]. Treatment may commence at 100 mg three times
daily increasing to 600 mg three times daily. Like midodrine, it should be
given during waking hours and avoided before bedtime to avoid supine
hypertension. Side effects include headache, dizziness, nausea, fatigue and
supine hypertension. Caution is advised in patients with congestive heart
failure and chronic renal failure.
Atomoxetine is a noradrenaline reuptake inhibitor which exerts a vasopres-
sor effect and is an emerging therapy for OH. In a randomised controlled trial,
atomoxetine produced a greater pressor response in upright systolic blood
pressure compared with midodrine [43]. Further clinical trials of this agent
are required. The most common side effects are decreased appetite, dry mouth,
insomnia and nausea. Severe hepatitis has been anecdotally reported.
Fludrocortisone is often used off-label to treat OH but evidence for its use is
low and it is recommended by consensus opinion only [44••]. It acts by
increasing renal sodium and water reabsorption, thus expanding intravascular
blood volume. There may be long-term effects of increased vascular resistance.
Treatment begins at 100 μg once daily increasing to 200 μg once daily. Side
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effects include supine hypertension, hypokalemia and oedema. Caution is
advised in patients with congestive heart failure.
Cholinesterase inhibitors such as pyridostigmine have been suggested as
treatments for OH. Most patients with neurodegenerative dementias will al-
ready be on cholinesterase inhibitors. Lower rates of OH have been reported in
a Cochrane review of rivastigmine treatment for PDD [45] and improved
responses to orthostasis in AD have been shown [46]. However, another study
has shown worsened heart rate variability in people with dementia treated with
donepezil [47].
Supine hypertension
Supine hypertension in neurogenic OH patients is arbitrarily defined as a
systolic blood pressure above 150 mmHg or diastolic pressure above
90 mmHg while in the supine position [44••]. It is common in patients with
chronic ANS dysfunction and difficult tomanage because its treatment has to be
balanced with treatment for OH, with management of one condition often
exacerbating the other. Expert recommendations for themanagement of supine
hypertension in the setting of neurogenic OH suggest that supine hypertension
requires intervention if systolic blood pressure exceeds the range of 160–
180 mmHg, but in patients with the largest drops in orthostatic BP, this may
have to be tolerated to avoid symptoms of OH and the increased risk of falls
[44••]. Patients with neurogenic OH and supine hypertension should be
advised to avoid supine posture during the day and elevate the head of the
bed as tolerated during the night. Fludrocortisone should be avoided and short-
acting antihypertensives such as captopril 25 mg, hydralazine 10–25 mg or
nitroglycerine patch (0.1 mg/h, remove in the morning) may be given at night.
Patients should be warned about the risk of falls when getting up at night
because of OH; a bedside urinal or commode may be required.
Dysphagia and sialorrhoea
Patients with dysphagia should be referred to a speech and language therapist.
Useful interventions may include postural and behavioural changes such as
reduced meal volumes and slow eating. Expiratory muscle strength training
(EMST) and video-assisted swallowing therapy (VAST) may be effective dys-
phagia treatments in PD [48]. A randomised control trial exploring interven-
tions to prevent aspiration including 132 PDD with dysphagia found lower
rates of aspiration as evidenced on videofluoroscopy, with honey-thickened
fluids [49]. Another study noted improved swallowing function objectively in
48 Lewy body dementia patients referred for videofluoroscopy with carbonated
liquids [50]. In patients with severe dementia, it may be appropriate to consider
at risk feeding, in which the risk of aspiration is tolerated in order to improve
quality of life [51].
Sialorrhoea is often due to reduced swallowing frequency and a portable
metronomic brooch to act as a reminder to swallow may help. Local anticho-
linergics are not suitable for patients with dementia because of their cognitive
side effects. A randomised cross-over trial of glycopyrrolate (1 mg, twice or
three times a day) in 23 PD patients found that 9 of patients had a clinically
relevant improvement in sialorrhoea 75 over a 4-week period [52]. Side effects
include dry mouth, urinary retention, constipation and blurred vision. An
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evidence-based review of botulinum toxin injection to the salivary glands
appears effective and safe in PD, although repeat injections are typically re-
quired every 3 to 6 months [53].
Gastroparesis
Dietary modifications, including a low-fat diet with small frequent meals and
liquid nutrients, can help with gastroparesis [2•]. D2 receptor blockers such as
metoclopramide and domperidone have been used but are associated with an
increase in the QT interval and risk of arrhythmia. Erythromycin and
azithromycin stimulate motilin receptors but adverse events include gastroin-
testinal toxicity, ototoxicity, antibiotic resistance and QT prolongation. Musca-
rinic agonists and cholinesterase inhibitors may be used but many patientsmay
already be on cholinesterase inhibitors. Ghrelin receptor agonists are being
tested in clinical trials [54].
Constipation
Non-pharmacological interventions may help with the initial management
of constipation. These include increasing the amount of fibre in the diet,
increasing fluid intake and increasing physical activity. Medications which
may exacerbate constipation such as anticholinergic agents and opiates
should be reviewed. One controlled clinical trial found that fermented
milk products with probiotics (e.g. kefir) resulted in a higher increase in
the number of complete bowel movements in patients with PD [55].
Pharmacological interventions include the use of bulk laxatives such as
psyllium and osmotic laxatives such as polyethylene glycol (macrogol). Psylli-
um has been shown to increase the frequency of bowel movement in PD
patients [56]. A randomised controlled trial of macrogol showed an improve-
ment in symptoms of constipation in PDpatients [57]. Lubiprostone is a locally
acting chloride type 2 channel activator. In a randomised controlled clinical trial
of PD patients, a marked or very marked clinical global improvement was
reported by 16 of 25 (64.0%) subjects receiving drug vs 5 of 27 (18.5%) subjects
receiving placebo [58].
Urinary tract symptoms
Urinary symptoms in ANS dysfunction may be related to detrusor overac-
tivity or underactivity. Non-pharmacological interventions include increas-
ing fluid intake because concentrated urine may exacerbate detrusor over-
activity. Bladder training may help and has been found to be useful in a
recent pilot trial in PD, but has not been investigated in dementia and may
be more difficult for dementia patients to undertake.
Anti-muscarinic drugs which are usually used to treat detrusor overac-
tivity are better avoided in dementia because of their cognitive side effects.
Mirabegron is a selective β3-adrenergic receptor which elicits relaxation of
the detrusor muscle during the storage phase and improves bladder capac-
ity. It has been suggested as an option for the management of urinary
symptoms in dementia by the National Institute of Health and Clinical
Excellence [59]. Treatment can be commenced at 25–50 mg once daily.
Side effects include urinary retention, pelvic/abdominal pain and
hypertension.
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Incomplete bladder emptying is uncommon in dementia but can occur if
ANS dysfunction is present. If the post-void residual is greater than 100 ml,
then intermittent self-catheterisation can be considered. This may need to be
performed by a caregiver. If this is not possible, then an indwelling cathetermay
have to be considered.
Sexual dysfunction
Erectile dysfunction, problems with ejaculation and difficulty achieving orgasm
are common in ANS dysfunction. Contributing factors such as stress, depres-
sion, anxiety and medications should be considered. Diuretics, β-blockers and
selective serotonin reuptake inhibitors can all cause erectile dysfunction. Op-
tions for management of erectile dysfunction include phosphodiesterase type 5
(PDE-5) inhibitors, intracavernosal injection therapy, vacuum pump devices,
intraurethral prostaglandin suppositories and surgical placement of penile
prostheses. When prescribing PDE 5 inhibitors, a short-acting agent such as
sildenafil should be used because of the risk of hypotension.
Sweating
Excessive sweating is common in PD patients. There are no treatment trials but
there was a consensus from a recent expert Delphi panel group that patients
may benefit from the use of loose-fitting clothing, cotton bedding for night
sweats and antiperspirants as well as avoidance of triggers, e.g. alcohol, spicy
foods and hot rooms [60].
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